FDA, USPTO Collaboration Could Expand Review Of Pharma Patents, Explore ‘Skinny Label’ Policy

 
• By Brenda Sandburg

The two agencies are pursuing initiatives to address instances of patents being used improperly to delay competition. FDA may play greater role in PTAB proceedings and training patent examiners.

Patent collaboration
US FDA and USPTO team up to assure patents do not delay generic and biosimilar competition • Source: Shutterstock

More from Legal & IP

More from Pink Sheet